Resveratrol and p53: How are they involved in CRC plasticity and apoptosis?
Journal of Advanced Research · 2024-12 · 66 · 181-195
DOI: 10.1016/j.jare.2024.01.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Advanced Research, 2024-12. Verfasst von Aranka Brockmueller und 3 weiteren Autor:innen. Beteiligte Einrichtung: Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, Ludwig-Maximilians-University Munich, Pettenkoferstr. 11, D-80336 Munich, Ger…. Hauptthemen laut MEDLINE: Resveratrol, Tumor Suppressor Protein p53, Apoptosis, Colorectal Neoplasms. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Colorectal cancer (CRC), which is mainly caused by epigenetic and lifestyle factors, is very often associated with functional plasticity during its development. In addition, the malignant plasticity of CRC cells underscores one of their survival abilities to functionally adapt to specific stresses, including inflammation, that occur during carcinogenesis. This leads to the generation of various subsets of cancer cells with phenotypic diversity and promotes epithelial-mesenchymal transition (EMT), formation of cancer cell stem cells (CSCs) and metabolic reprogramming. This can enhance cancer cell differentiation and facilitate tumorigenic potential, drug resistance and metastasis. AIM OF REVIEW: The tumor protein p53 acts as one of the central suppressors of carcinogenesis by regulating its target genes, whose proteins are involved in the plasticity of cancer cells, autophagy, cell cycle, apoptosis, DNA repair. The aim of this review is to summarize the latest published research on resveratrol's effect in the prevention of CRC, its regulatory actions, specifically on the p53 pathway, and its treatment options. KEY SCIENTIFIC CONCEPTS OF REVIEW: Resveratrol, a naturally occurring polyphenol, is a potent inducer of a variety of tumor-controlling. However, the underlying mechanisms linking the p53 signaling pathway to the functional anti-plasticity effect of resveratrol in CRC are still poorly understood. Therefore, this review discusses novel relationships between anti-cellular plasticity/heterogeneity, pro-apoptosis and modulation of tumor protein p53 signaling in CRC oncogenesis, as one of the crucial mechanisms by which resveratrol prevents malignant phenotypic changes leading to cell migration and drug resistance, thus improving the ongoing treatment of CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, Ludwig-Maximilians-University Munich, Pettenkoferstr. 11, D-80336 Munich, Germany.
- Institute of Anatomy and Cell Biology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
- Department of Clinical Nutrition, School of Nutrition & Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
- Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, Ludwig-Maximilians-University Munich, Pettenkoferstr. 11, D-80336 Munich, Germany. Electronic address: mehdi.shakibaei@med.uni-muenchen.de.
Zitieren
APA
Brockmueller, A., Buhrmann, C., Moravejolahkami, A. R., & Shakibaei, M. (2024). Resveratrol and p53: How are they involved in CRC plasticity and apoptosis?. Journal of Advanced Research, 66, 181-195. https://doi.org/10.1016/j.jare.2024.01.005
Vancouver
Brockmueller A, Buhrmann C, Moravejolahkami AR, Shakibaei M. Resveratrol and p53: How are they involved in CRC plasticity and apoptosis?. Journal of Advanced Research. 2024;66:181-195. doi:10.1016/j.jare.2024.01.005
BibTeX
@article{Brockmueller2024,
author = {Brockmueller, Aranka and Buhrmann, Constanze and Moravejolahkami, Amir Reza and Shakibaei, Mehdi},
title = {Resveratrol and p53: How are they involved in CRC plasticity and apoptosis?},
journal = {Journal of Advanced Research},
year = {2024},
volume = {66},
pages = {181--195},
doi = {10.1016/j.jare.2024.01.005}
}
EUVIMED